British pharmaceutical giant AstraZeneca announced Sunday “groundbreaking” results in a trial of a new breast cancer drug which they say has been proven to reduce the risk of death or disease progression by 72 percent, compared to existing treatments.
The drug company said the results of its trial of Enhertu medication in treating the currently incurable HER-2-positive breast cancer showed “a strong trend towards improved overall survival.”
AstraZeneca said Enherthu, when coupled with chemotherapy, was shown to be twice as effective in controlling the disease as the similarly intravenous antibody drug TDM1, the current standard of care medication.
Three-quarters of the 500 trial patients from around the globe who had been administered Enherthu showed no progression in their cancer after 12 months, compared to 34.1% of those treated with TDM1. Additionally, progression-free survival improved from 7.2 months to 25.1 months.
In total, 94.1% of Enhertu patients survived 12 months of treatment, compared to 85.9% of TDM1 patients.
Read more at Times of Israel.
{Matzav.com}
